SomnoMed Toekomstige groei

ASX:SOM - Toekomstschattingen van analisten en financiële gegevens uit het verleden (AUD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
6/30/2026	110	N/A	N/A	N/A	1
6/30/2025	100	N/A	N/A	N/A	1
6/30/2024	92	-12	-12	-6	N/A
3/31/2024	90	-11	-11	-6	N/A
12/31/2023	89	-11	-10	-5	N/A
9/30/2023	86	-9	-10	-4	N/A
6/30/2023	84	-8	-10	-4	N/A
3/31/2023	81	-7	-11	-3	N/A
12/31/2022	79	-5	-11	-2	N/A
9/30/2022	76	-5	-9	0	N/A
6/30/2022	73	-4	-7	2	N/A
3/31/2022	69	-5	-6	1	N/A
12/31/2021	66	-5	-6	-1	N/A
9/30/2021	64	-3	-4	1	N/A
6/30/2021	63	-1	-1	3	N/A
3/31/2021	59	-1	2	5	N/A
12/31/2020	55	-1	5	7	N/A
9/30/2020	56	-1	4	6	N/A
6/30/2020	57	0	3	5	N/A
3/31/2020	60	0	0	2	N/A
12/31/2019	63	1	-4	-1	N/A
9/30/2019	61	0	-6	-4	N/A
6/30/2019	59	0	-8	-7	N/A
3/31/2019	58	2	N/A	N/A	N/A
12/31/2018	56	3	-9	-7	N/A
9/30/2018	54	3	-10	-8	N/A
6/30/2018	52	2	-12	-9	N/A
3/31/2018	51	-1	N/A	N/A	N/A
12/31/2017	50	-4	N/A	-8	N/A
9/30/2017	50	-4	N/A	-5	N/A
6/30/2017	49	-3	N/A	-3	N/A
3/31/2017	48	-2	N/A	-1	N/A
12/31/2016	47	-1	N/A	0	N/A
9/30/2016	45	0	N/A	1	N/A
6/30/2016	44	0	N/A	2	N/A
3/31/2016	42	0	N/A	2	N/A
12/31/2015	39	1	N/A	1	N/A
9/30/2015	37	1	N/A	0	N/A
6/30/2015	34	1	N/A	0	N/A
3/31/2015	34	1	N/A	0	N/A
12/31/2014	35	1	N/A	-1	N/A
9/30/2014	32	1	N/A	-1	N/A
6/30/2014	30	0	N/A	-1	N/A
3/31/2014	26	0	N/A	0	N/A
12/31/2013	22	0	N/A	0	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er zijn onvoldoende gegevens om te bepalen of de verwachte winstgroei van SOM boven de spaarquote ( 2.6% ) ligt.

Winst versus markt: Er zijn onvoldoende gegevens om te bepalen of de winst van SOM naar verwachting sneller zal groeien dan de markt Australian

Hoge groeiwinsten: Er zijn onvoldoende gegevens om te bepalen of de winst van SOM naar verwachting de komende 3 jaar aanzienlijk zal groeien.

Omzet versus markt: De omzet van SOM ( 9% per jaar) zal naar verwachting sneller groeien dan de markt Australian ( 5.6% per jaar).

Hoge groei-inkomsten: De omzet van SOM ( 9% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen SOM zal naar verwachting over 3 jaar laag zijn ( 4.9 %).

SomnoMed Toekomstige groei

Future criteriumcontroles 1/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target increased by 25% to AU$2.07

Price target decreased by 12% to AU$1.88

Consensus forecasts updated

Consensus forecasts updated

SomnoMed Limited Provides Earnings Guidance for the Year 2023

Price target decreased to AU$2.16

Recent updates

SomnoMed Limited, Annual General Meeting, Nov 27, 2024

SomnoMed Limited, Annual General Meeting, Nov 27, 2024

Benign Growth For SomnoMed Limited (ASX:SOM) Underpins Stock's 27% Plummet

SomnoMed Limited Announces Board Changes

Full year 2024 earnings released: AU$0.10 loss per share (vs AU$0.10 loss in FY 2023)

Full year 2024 earnings released: AU$0.10 loss per share (vs AU$0.10 loss in FY 2023)

SomnoMed Limited to Report Fiscal Year 2024 Results on Aug 28, 2024

SomnoMed Limited's (ASX:SOM) Share Price Boosted 30% But Its Business Prospects Need A Lift Too

SomnoMed Limited (ASX:SOM) Shares Fly 30% But Investors Aren't Buying For Growth

New major risk - Shareholder dilution

SomnoMed Limited (ASX:SOM) Stock's 43% Dive Might Signal An Opportunity But It Requires Some Scrutiny

New major risk - Share price stability

No independent directors

SomnoMed Limited has filed a Follow-on Equity Offering in the amount of AUD 22.6 million.

Price target increased by 25% to AU$2.07

SomnoMed (ASX:SOM) Has Debt But No Earnings; Should You Worry?

SomnoMed Limited to Report First Half, 2024 Results on Feb 28, 2024

Market Still Lacking Some Conviction On SomnoMed Limited (ASX:SOM)

New major risk - Revenue and earnings growth

SomnoMed Limited, Annual General Meeting, Nov 24, 2023

SomnoMed Limited Announces Resignation of Hilton Brett as Non-Executive Director

SomnoMed Limited has completed a Follow-on Equity Offering in the amount of AUD 15.499249 million.

SomnoMed Limited has completed a Follow-on Equity Offering in the amount of AUD 15.498845 million.

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

SomnoMed Limited (ASX:SOM) Could Be Riskier Than It Looks

Full year 2023 earnings: Revenues in line with analyst expectations

New minor risk - Financial data availability

SomnoMed Limited to Report Q4, 2023 Results on Aug 24, 2023

Somnomed Limited Announces Executive Changes

Is SomnoMed (ASX:SOM) Using Too Much Debt?

Price target decreased by 12% to AU$1.88

First half 2023 earnings released: AU$0.047 loss per share (vs AU$0.038 loss in 1H 2022)

It's Unlikely That SomnoMed Limited's (ASX:SOM) CEO Will See A Huge Pay Rise This Year

No independent directors

SomnoMed Limited, Annual General Meeting, Nov 25, 2022

SomnoMed (ASX:SOM) Has Debt But No Earnings; Should You Worry?

Consensus forecasts updated

Consensus forecasts updated

Full year 2022 earnings: EPS misses analyst expectations

SomnoMed Limited Provides Earnings Guidance for the Year 2023

Price target decreased to AU$2.16

Is SomnoMed (ASX:SOM) Using Debt Sensibly?

No independent directors

Global CEO recently sold AU$81k worth of stock

SomnoMed Introduces Rest Assure

First half 2022 earnings: EPS and revenues miss analyst expectations

SomnoMed Introduces Rest Assure

SomnoMed Limited to Report First Half, 2022 Results on Feb 22, 2022

SomnoMed Limited Announces World First Technology Enabled Oral Appliance

Chairman of the Board recently bought AU$499k worth of stock

Is SomnoMed (ASX:SOM) Using Debt Sensibly?

Full year 2021 earnings released: AU$0.014 loss per share (vs AU$0.007 loss in FY 2020)

Non-Executive Director recently bought AU$81k worth of stock

Full year 2021 earnings released: AU$1.38 loss per share (vs AU$0.007 loss in FY 2020)

Non-Executive Director recently bought AU$81k worth of stock

Health Check: How Prudently Does SomnoMed (ASX:SOM) Use Debt?

Could The SomnoMed Limited (ASX:SOM) Ownership Structure Tell Us Something Useful?

First half 2021 earnings released: EPS AU$0.008 (vs AU$0.014 in 1H 2020)

New 90-day low: AU$1.83

Have Insiders Been Buying SomnoMed Limited (ASX:SOM) Shares?

Is SomnoMed (ASX:SOM) Using Debt In A Risky Way?

Is SomnoMed Limited (ASX:SOM) Trading At A 38% Discount?

Somnomed Limited Appoints Karen Borg to Board of Directors, Effective November 26, 2020

New 90-day high: AU$2.45

Full year earnings released - AU$0.0069 loss per share

New 90-day high: AU$2.14

Chairman of the Board recently bought AU$203k worth of stock

New 90-day high - AU$1.58